Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
July 12, 2013 -- Because of scandals in China – first a retraction of a scientific article, then the bribery accusations – GlaxoSmithKline’s China operations have cast a pall over the entire company’s reputation. An even larger question is whether the company’s problems will spill over to affect other multinational pharmas that are also operating in China. In particular, will Glaxo’s misfortunes deal a blow to R&D in China? According to Greg B. Scott, CEO of ChinaBio®, it is unfortunate that the Glaxo’s R&D scandal came at a time when researchers in China have yet to prove their worth. More details....
Stock Symbol: (NYSE: GSK)
Help employers find you! Check out all the jobs and post your resume.
